D-0732-2026 Class I Ongoing

Recalled by JB Chemicals And Pharmaceuticals Ltd — Mumbai, N/A

FDA drug recall D-0732-2026 was initiated by JB Chemicals And Pharmaceuticals Ltd on Jun 24, 2026 and is designated Class I. Reason for recall: Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine. The recall status is ongoing. Affected quantity: 34,020 100-count bottles.

Recall details

Product Type
Drugs
Report Date
Jul 29, 2026
Initiation Date
Jun 24, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
34,020 100-count bottles.

Product description

Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-401-10.

Reason for recall

Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.

Distribution pattern

Nationwide in the USA

Code information

Lots: GY825029, GY825030, GY825031, GY825032, expires: 2028-OCT

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0732-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0732-2026. Report a data issue: hello@regdatalab.com.